| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 13 Nov 2026 | S-8 |
| 12 Nov 2026 | SCHEDULE 13G/A |
| 10 Nov 2026 | 10-Q |
| 10 Nov 2026 | SCHEDULE 13D/A |
| 10 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Autolus Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates November 10, 2026 at 7:00 AM EST Company reports AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $41.2 million, an increase of 95%... |
| 22 Sep 2026 | EFFECT |
| 22 Sep 2026 | 424B3 |
| 15 Sep 2026 | DEL AM |
| 14 Sep 2026 | S-3 |
| 03 Sep 2026 |
Form 4: Piccina Cintia, U.S. CCO & Country Gen Manager
Received 20,000 shares by exercise or conversion ($47K) · Sold 6,713 shares ($15.7K) |
| 02 Sep 2026 | 144 |
| 28 Aug 2026 | SCHEDULE 13D/A |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 11 Aug 2026 | 10-Q |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Autolus Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates August 11, 2026 at 7:00 AM EDT Company reports AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $45.7 million in Q2 2026, an incre... |
| 03 Aug 2026 |
8-K: Regulation FD Disclosure; Other Events
Autolus Therapeutics Reports Preliminary Second Quarter 2026 Net Product Revenue and Announces Credit Facility of up to $250 Million with Perceptive Advisors August 3, 2026 at 7:13 AM EDT Company reports preliminary Q2 2026 AUCATZYL net ... |
| 03 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more
Other Equity Interests owned or held by the Issuer or its Subsidiaries |
| 01 Jul 2026 |
Form 4: Young William D, Director
Granted 31,667 Restricted Share Units · Granted 47,500 Share Option (Right to Buy) |
| 01 Jul 2026 |
Form 4: Rao Madduri Ravin, Director
Granted 31,667 Restricted Share Units · Granted 47,500 Share Option (Right to Buy) |
Loading...